Summit Therapeutics (SMMT) investor relations material

Executive summary

• Focused on developing ivonescimab, a novel bispecific antibody for oncology, with multiple ongoing and planned Phase III trials in NSCLC, CRC, and head and neck cancers, and expanded licensing territory to Latin America, Middle East, and Africa.

• Over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 70,000 in commercial settings in China.

• Submitted a BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC; FDA accepted filing with a PDUFA date of November 14, 2026, but noted OS benefit is required for approval.

• Entered collaborations with Revolution Medicines, GSK, and GORTEC for combination studies and new indications with ivonescimab.

Financial highlights

• Net loss of $189.4 million for Q1 2026, up from $62.9 million in Q1 2025, driven by increased R&D and stock-based compensation.

• Operating expenses rose to $195.2 million (Q1 2026) from $66.9 million (Q1 2025), with R&D at $132.6 million and G&A at $62.6 million.

• Cash and cash equivalents and short-term investments totaled $598.7 million at March 31, 2026, down from $713.4 million at December 31, 2025.

• Cash used in operating activities was $122.3 million for Q1 2026.

• Non-GAAP net loss was $116.6 million ($0.15 per share) versus $51.8 million ($0.07 per share) in Q1 2025.

Outlook and guidance

• Expects continued operating losses and increased R&D and G&A expenses as clinical development of ivonescimab progresses.

• Current cash and investments are insufficient to fund operations for the next 12 months; additional capital will be required.

• Final PFS data for the HARMONI-3 squamous cohort expected in the second half of 2026; interim OS analyses planned.

• PFS data for the HARMONI-3 non-squamous cohort expected in the first half of 2027.

• Evaluating financing options including equity, debt, collaborations, and licensing.